Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment

Yuichirou Yano, Satoshi Hoshide, motohiro shimizu, Kazuo Eguchi, Joji Ishikawa, Shizukiyo Ishikawa, Kazuyuki Shimada, Kazuomi Kario

研究成果: ジャーナルへの寄稿記事

16 引用 (Scopus)

抄録

Background Our aim was to assess whether home blood pressure (HBP) and ambulatory BP monitoring measurement (ABPM), in addition to office BP (OBP) predict changes of cardiovascular biomarkers during antihypertensive treatment. Methods Two hundred and fifty-two hypertensive patients (mean age, 68 years; men: 41%) underwent measurements of OBP, HBP, ABPM, and cardiovascular biomarkers (urinary albumin excretion (UAE) and brain natriuretic peptide (BNP)) before and after 6 months of treatment with candesartan (± thiazide-diuretics). Results During the intervention, the OBP, HBP, daytime and night-time BP, and UAE levels were all significantly reduced (all P< 0.01). BNP was reduced only in the patients using diuretics (P = 0.003). For predicting the treatment-induced change in UAE, each of home systolic BP (SBP) and night-time SBP changes, but not daytime SBP change, had independent and significant value beyond OBP measurement (both P< 0.05). In contrast, for predicting the treatment-induced change in BNP, night-time SBP changes, but not home or daytime SBP changes, had significant value beyond OBP measurement (both P< 0.05). Patients who achieved a reduction in all three SBP parameters (office, home, and night-time SBP; n = 122) showed a more significant reduction of UAE compared with those who did not (52.6 vs. 32.5%; P = 0.001), and patients who achieved a reduction in both office and night-time SBP (n = 134) showed a more significant reductions of BNP than those who did not (12.9 vs. 12.8%; P< 0.05). Conclusions HBP and ABPM measurements, particularly night-time SBP values provide additional information for predicting treatment-induced changes of cardiovascular biomarkers when used in conjunction with office SBP measurement during antihypertensive treatment.

元の言語英語
ページ(範囲)306-312
ページ数7
ジャーナルAmerican Journal of Hypertension
25
発行部数3
DOI
出版物ステータス出版済み - 3 1 2012

Fingerprint

Antihypertensive Agents
Biomarkers
Brain Natriuretic Peptide
Blood Pressure
Ambulatory Blood Pressure Monitoring
Albumins
Therapeutics
Sodium Chloride Symporter Inhibitors
Diuretics

All Science Journal Classification (ASJC) codes

  • Internal Medicine

これを引用

Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment. / Yano, Yuichirou; Hoshide, Satoshi; shimizu, motohiro; Eguchi, Kazuo; Ishikawa, Joji; Ishikawa, Shizukiyo; Shimada, Kazuyuki; Kario, Kazuomi.

:: American Journal of Hypertension, 巻 25, 番号 3, 01.03.2012, p. 306-312.

研究成果: ジャーナルへの寄稿記事

Yano, Y, Hoshide, S, shimizu, M, Eguchi, K, Ishikawa, J, Ishikawa, S, Shimada, K & Kario, K 2012, 'Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment', American Journal of Hypertension, 巻. 25, 番号 3, pp. 306-312. https://doi.org/10.1038/ajh.2011.229
Yano, Yuichirou ; Hoshide, Satoshi ; shimizu, motohiro ; Eguchi, Kazuo ; Ishikawa, Joji ; Ishikawa, Shizukiyo ; Shimada, Kazuyuki ; Kario, Kazuomi. / Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment. :: American Journal of Hypertension. 2012 ; 巻 25, 番号 3. pp. 306-312.
@article{4e60875ca55a4e19b7536e891a283e47,
title = "Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment",
abstract = "Background Our aim was to assess whether home blood pressure (HBP) and ambulatory BP monitoring measurement (ABPM), in addition to office BP (OBP) predict changes of cardiovascular biomarkers during antihypertensive treatment. Methods Two hundred and fifty-two hypertensive patients (mean age, 68 years; men: 41{\%}) underwent measurements of OBP, HBP, ABPM, and cardiovascular biomarkers (urinary albumin excretion (UAE) and brain natriuretic peptide (BNP)) before and after 6 months of treatment with candesartan (± thiazide-diuretics). Results During the intervention, the OBP, HBP, daytime and night-time BP, and UAE levels were all significantly reduced (all P< 0.01). BNP was reduced only in the patients using diuretics (P = 0.003). For predicting the treatment-induced change in UAE, each of home systolic BP (SBP) and night-time SBP changes, but not daytime SBP change, had independent and significant value beyond OBP measurement (both P< 0.05). In contrast, for predicting the treatment-induced change in BNP, night-time SBP changes, but not home or daytime SBP changes, had significant value beyond OBP measurement (both P< 0.05). Patients who achieved a reduction in all three SBP parameters (office, home, and night-time SBP; n = 122) showed a more significant reduction of UAE compared with those who did not (52.6 vs. 32.5{\%}; P = 0.001), and patients who achieved a reduction in both office and night-time SBP (n = 134) showed a more significant reductions of BNP than those who did not (12.9 vs. 12.8{\%}; P< 0.05). Conclusions HBP and ABPM measurements, particularly night-time SBP values provide additional information for predicting treatment-induced changes of cardiovascular biomarkers when used in conjunction with office SBP measurement during antihypertensive treatment.",
author = "Yuichirou Yano and Satoshi Hoshide and motohiro shimizu and Kazuo Eguchi and Joji Ishikawa and Shizukiyo Ishikawa and Kazuyuki Shimada and Kazuomi Kario",
year = "2012",
month = "3",
day = "1",
doi = "10.1038/ajh.2011.229",
language = "English",
volume = "25",
pages = "306--312",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment

AU - Yano, Yuichirou

AU - Hoshide, Satoshi

AU - shimizu, motohiro

AU - Eguchi, Kazuo

AU - Ishikawa, Joji

AU - Ishikawa, Shizukiyo

AU - Shimada, Kazuyuki

AU - Kario, Kazuomi

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Background Our aim was to assess whether home blood pressure (HBP) and ambulatory BP monitoring measurement (ABPM), in addition to office BP (OBP) predict changes of cardiovascular biomarkers during antihypertensive treatment. Methods Two hundred and fifty-two hypertensive patients (mean age, 68 years; men: 41%) underwent measurements of OBP, HBP, ABPM, and cardiovascular biomarkers (urinary albumin excretion (UAE) and brain natriuretic peptide (BNP)) before and after 6 months of treatment with candesartan (± thiazide-diuretics). Results During the intervention, the OBP, HBP, daytime and night-time BP, and UAE levels were all significantly reduced (all P< 0.01). BNP was reduced only in the patients using diuretics (P = 0.003). For predicting the treatment-induced change in UAE, each of home systolic BP (SBP) and night-time SBP changes, but not daytime SBP change, had independent and significant value beyond OBP measurement (both P< 0.05). In contrast, for predicting the treatment-induced change in BNP, night-time SBP changes, but not home or daytime SBP changes, had significant value beyond OBP measurement (both P< 0.05). Patients who achieved a reduction in all three SBP parameters (office, home, and night-time SBP; n = 122) showed a more significant reduction of UAE compared with those who did not (52.6 vs. 32.5%; P = 0.001), and patients who achieved a reduction in both office and night-time SBP (n = 134) showed a more significant reductions of BNP than those who did not (12.9 vs. 12.8%; P< 0.05). Conclusions HBP and ABPM measurements, particularly night-time SBP values provide additional information for predicting treatment-induced changes of cardiovascular biomarkers when used in conjunction with office SBP measurement during antihypertensive treatment.

AB - Background Our aim was to assess whether home blood pressure (HBP) and ambulatory BP monitoring measurement (ABPM), in addition to office BP (OBP) predict changes of cardiovascular biomarkers during antihypertensive treatment. Methods Two hundred and fifty-two hypertensive patients (mean age, 68 years; men: 41%) underwent measurements of OBP, HBP, ABPM, and cardiovascular biomarkers (urinary albumin excretion (UAE) and brain natriuretic peptide (BNP)) before and after 6 months of treatment with candesartan (± thiazide-diuretics). Results During the intervention, the OBP, HBP, daytime and night-time BP, and UAE levels were all significantly reduced (all P< 0.01). BNP was reduced only in the patients using diuretics (P = 0.003). For predicting the treatment-induced change in UAE, each of home systolic BP (SBP) and night-time SBP changes, but not daytime SBP change, had independent and significant value beyond OBP measurement (both P< 0.05). In contrast, for predicting the treatment-induced change in BNP, night-time SBP changes, but not home or daytime SBP changes, had significant value beyond OBP measurement (both P< 0.05). Patients who achieved a reduction in all three SBP parameters (office, home, and night-time SBP; n = 122) showed a more significant reduction of UAE compared with those who did not (52.6 vs. 32.5%; P = 0.001), and patients who achieved a reduction in both office and night-time SBP (n = 134) showed a more significant reductions of BNP than those who did not (12.9 vs. 12.8%; P< 0.05). Conclusions HBP and ABPM measurements, particularly night-time SBP values provide additional information for predicting treatment-induced changes of cardiovascular biomarkers when used in conjunction with office SBP measurement during antihypertensive treatment.

UR - http://www.scopus.com/inward/record.url?scp=84857065363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857065363&partnerID=8YFLogxK

U2 - 10.1038/ajh.2011.229

DO - 10.1038/ajh.2011.229

M3 - Article

VL - 25

SP - 306

EP - 312

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 3

ER -